The article discusses the need for sustained demand and funding for HIV treatment in sub-Saharan Africa. Bekker emphasizes the reliance on donor funding amid concerns that governments are hesitant to include generic products in their budgets. Clinicians warn that a shift in focus from prevention to treatment could lead to rising infection rates. Additionally, long-term HIV infections, despite treatment, are linked to increased risks for metabolic disorders like hypertension and diabetes, highlighting the necessity for innovative treatment strategies, including lenacapavir, to address both HIV and these associated health risks.
It requires a nice healthy demand to ensure that for each of the generic companies, it's going to be worth their while, says Bekker.
HIV itself disrupts your metabolism, as do many of the antiretrovirals. We see the same chronic diseases in people living with HIV as we do in the general population.
Collection
[
|
...
]